Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 20, 2019
Event: Presentation of clinical trial data at the 16th International Congress for the Society for Melanoma Research.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the presentation of data from the Company's ongoing Phase 1/2 clinical trial titled "A Phase 1/2 Study in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions" (ClinicalTrials.gov Identifier: NCT03947385). No financial changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Risks
Management Commentary: The Company announced the presentation of clinical data on the specified date. The full text of the press release is furnished as Exhibit 99.1.
Legal Status of Information: The information in Item 8.01 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor subject to the liabilities of that section, unless expressly incorporated by reference in another filing.
Emerging Growth Company: The registrant is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific clinical trial data results and safety profiles.
- Verify the status of the Phase 1/2 study (NCT03947385) on ClinicalTrials.gov for enrollment and endpoint details.
- Check subsequent filings (e.g., 10-Q or 10-K) for financial impacts related to clinical trial progress.
- Confirm the Company's cash runway and funding status in the most recent quarterly report, as this 8-K contains no liquidity data.